Foundayo vs. Oral Wegovy vs. Zepbound: Making Sense of the GLP-1 Options
Not all GLP-1s are the same. And for the first time in this drug class, you actually have real choices.
With orforglipron (Foundayo) now FDA-approved and oral Wegovy (25 mg semaglutide) newly available, patients and doctors face a genuinely thought-provoking question: which oral option is right for me?
Let’s break it down without the marketing noise.
Two Oral GLP-1s, Two Very Different Drugs
Orforglipron (Foundayo) — a daily pill with no fasting, food, or water restrictions. Take it with your morning coffee. Take it with breakfast. No waiting.
Oral semaglutide (Wegovy 25 mg tablet) — also a daily pill, but you take it on an empty stomach and wait 30 minutes before eating or drinking anything but water. Same class, completely different practical demands.
Both are GLP-1 receptor agonists. But the behavioral requirements are not even close.
The Weight Loss Numbers — in Real Terms
For someone starting at 220 pounds:
| Medication | Average Weight Loss | What’s the Catch |
|---|---|---|
| Orforglipron (Foundayo) | ~11-12% (≈ 25 lbs) | No fasting required |
| Oral Wegovy 25 mg | ~16-17% for those who stayed on it (≈ 35-37 lbs) | Must take on empty stomach, wait 30 min |
| Wegovy (standard dose) | ~15% (≈ 33 lbs) | Weekly injection |
| Wegovy HD (7.2 mg) | ~21% (≈ 46 lbs) | Weekly injection, higher dose |
| Zepbound (tirzepatide) | ~20% (≈ 44 lbs) | Weekly injection |
Important note on oral Wegovy: The 16.6% figure reflects patients who completed the full 64-week course. The intent-to-treat analysis showed 13.6% — meaning roughly 1 in 5 patients stopped early, most likely due to the fasting requirement or side effects. The 30-minute empty-stomach window is a real barrier for many people.
The ATTAIN-MAINTAIN Data: Switching to Oral
Here’s what the Phase 3 ATTAIN-MAINTAIN trial actually showed about switching from injectable GLP-1s to orforglipron:
From semaglutide (Wegovy) to orforglipron:
- Patients regained approximately 2 pounds over 52 weeks on orforglipron
- That’s essentially maintenance of prior weight loss
- Makes sense: orforglipron and semaglutide have similar efficacy ceilings
From tirzepatide (Zepbound) to orforglipron:
- Patients regained approximately 11 pounds over 52 weeks
- This is a meaningful difference — tirzepatide produces substantially more weight loss than orforglipron
- Switching from tirzepatide to orforglipron means accepting a step down in efficacy
Practical takeaway: If you’re stable on Zepbound and hitting your goals, switching to orforglipron means losing some of what you worked for. If you’re on Wegovy, the difference is negligible.
Where Orforglipron Actually Makes Sense
For patients earlier in their weight loss journey — say, someone with a BMI around 30 who hasn’t yet reached a plateau — orforglipron is a perfectly reasonable first GLP-1 choice. The convenience is real: no fasting, no injections, no refrigeration required. For someone who has never been on a GLP-1, 11-12% weight loss is an excellent outcome.
It’s also worth considering for people for whom the oral Wegovy fasting requirement was too challenging. If you tried oral semaglutide and couldn’t maintain the 30-minute empty-stomach window, orforglipron removes that barrier entirely.
Where Oral Wegovy Makes Sense
If you can make the fasting window work — and many patients do — oral Wegovy at 25 mg delivers meaningfully more weight loss than orforglipron. The OASIS-4 data shows 16.6% completion-rate weight loss, comparable to the injectable version.
If you’re the type of person who can take a pill at 6 AM and wait until 6:30 to eat breakfast, oral Wegovy is the stronger option. It requires routine, not injections.
The Price Question
| Medication | Approximate List Price | With Insurance Coverage |
|---|---|---|
| Oral Wegovy | $149-$299/month | As low as $25/month |
| Orforglipron (Foundayo) | $299/month | Same |
| Wegovy (injectable) | $349/month | Same |
| Wegovy HD | $449/month | Same |
| Zepbound | $299-$449/month | Same |
Important Medicare update: Starting July 1, 2026, Medicare Part D will cover glp-1 medications including Founday, Wegovy, Oral Wegovy and the Zepbound Kwikpen for obesity through the new Medicare GLP-1 Bridge program — a temporary demonstration running through December 31, 2027. For eligible beneficiaries, out-of-pocket costs are expected to be around $50/month. This is a significant shift that may make these medications accessible for many patients who previously had no coverage path. (CMS Medicare GLP-1 Bridge)
The Realistic Hierarchy
If maximum weight loss is the goal: Wegovy HD (21%) and Zepbound (20%) are the top tier.
If you want strong oral results but can tolerate the fasting requirement: oral Wegovy 25 mg — provided you can maintain the 30-minute empty-stomach protocol.
If you want a simple daily pill with no fasting drama: orforglipron (Foundayo) — accepting somewhat lower average weight loss in exchange for convenience.
The Bottom Line
The GLP-1 landscape is genuinely better than it was two years ago. More options means more people can find something that fits their life — not just their lab values.
If you’re earlier in your weight management journey and prefer a pill with no strings attached, orforglipron is worth discussing. If you’re willing to put up with the 30-minute fasting window and want more weight loss, oral Wegovy is the stronger oral option. If you’re on Zepbound and it’s working — stay on Zepbound.
The right medication is the one you’ll actually take consistently. Talk to your doctor about which category fits your life.
